Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B-cells. It depletes the level of mature B-cells by various mechanisms such as mediation of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and B-cell apoptosis. Rituximab is a USFDA approved drug for clinical use in non-Hodgkin's B-cell lymphoma (NHL), rheumatoid arthritis, chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis and pemphigus vulgaris. It is also known for its "off label" use in renal disease and renal transplant worldwide. However, the exact mechanisms by which it exerts its effect in the aforementioned condition remain unclear but may be related to its long-term effects on plasma cell development and the impact on B-cell modulation of T cell responses. This review discusses the current use of rituximab in renal disease and renal transplantation, and its potential role in novel therapeutic protocols.
| INTRODUC TI ON
Rituximab is a chimeric murine/human monoclonal IgG1 kappa monoclonal antibody that binds to the CD20 antigen present on the cell surface. 1 It is a product consisting of approximately 20% mouse and 80% human protein and was the first monoclonal antibody to be approved for clinical use in the therapy of cancer patients suffering from lymphoma. It is approved for use against indolent B-cell nonHodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) in patients with an incomplete response or intolerance to tumor necrosis inhibitors (TNFi), granulomatosis with polyangiitis and microscopic polyangiitis. 2, 3 Recently rituximab has been approved by the USFDA for pemphigus vulgaris. not express CD20 on their surfaces. 5 Rituximab depletes B-cells by various mechanisms, including mediation of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and B-cell apoptosis. 6 It has been shown to be efficacious in clinical trials of patients with RA and hematological malignancies, with a reasonable safety profile and a small risk of serious infectious events. Treatment effects were stable over time and repeated courses. Other opportunistic infections were rare with the treatment. 7, 8 Antibody production is a characteristic and pathological marker for number of systemic diseases. It may affect the kidneys and may lead to serious problems in renal transplantation.
Rituximab is known for its "off label" use for the treatment of various disorders, but the exact mechanism by which it exerts its effect remains unclear. It is used to treat systemic lupus erythematous, 9 membranous nephropathy, 10 mixed essential cryoglobulinemia, 11 focal segmental glomerulosclerosis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 12 and hemolytic uremic syndrome, 13 specifically in cases which are resistant to conventional therapy. In transplantation, it is used in induction/ desensitization in refractory-B-cell-associated or antibody-associated rejection. 14 Herein, we review the latest reports on the use
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of rituximab in kidney disease and transplantation. Randomized controlled trials are warranted for several of the indications discussed below, to confirm or refute the benefits reported to date.
| SYS TEMI C LUPUS ERY THEMATOSUS
Lupus nephritis is a major cause of mortality and morbidity in patients with SLE, 15 with renal involvement occurring in up to twothirds of patients. B-cells are thought to play a crucial role in the pathogenesis of SLE, including the production of autoantibodies, the regulation of T-cell activation, and the production of cytokines involved in the disease; 16 
| IDIOPATHIC MEMB R ANOUS NEPHROPATHY
Membranous nephropathy (MN) remains a leading cause of nephrotic syndrome in adults. In most patients, an underlying etiology for the lesion is unknown and the disorder is termed idiopathic. 19, 20 The M-type phospholipase A2 receptor (PLA2R), a transmembrane protein expressed on glomerular podocytes, has been demonstrated to be the target antigen in most cases of idiopathic
MN (IMN)
. 21 This creates a paradigm whereby circulating autoantibodies to PLA2R form in situ immune complexes at the level of the podocyte, leading to the development of MN. The central mechanistic role for autoantibodies in MN has provided a rationale for B-cell targeted therapy. 22 duced significantly from the baseline value to the 24-month value (P < 0.01). 24 Clinical outcomes of IMN patients treated with rituximab are summarized in Table 1 .
| MIXED ESSENTIAL CRYOGLOBULINEMIA
Mixed cryoglobulinemia is a systemic vasculitis, primarily mediated by immune complexes and is associated with hepatitis C virus (HCV) infection and B-cell lymphoproliferation. 25 Rituximab has the potential to deplete the expanded population of B-cells developing in HCV-associated vasculitis thereby reducing the formation of the cryoglobulin immune complex. 26 In a prospective rand- In a long-term, prospective, randomized controlled trial, De Vita et al reported that rituximab monotherapy represents a very good option for severe cryoglobulinemic vasculitis and can be maintained over the long term in most patients. Fifty-nine patients were randomized to nonrituximab (RTX) or RTX groups (two infusions of 1 g each). Survival of treatment at 12 months, the primary end point, was statistically higher in the RTX group (64.3% vs 3.5%; P < 0.0001), as well as at 3 months (92.9% vs 13.8%; P < 0.0001), 6 months (71.4% vs 3.5%; P < 0.0001), and 24 months (60.7% vs 3.5%; P < 0.0001). The Birmingham Vasculitis
Activity Score decreased only after treatment with rituximab (11.9 ± 5.4
at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). Overall, rituximab treatment was well tolerated.
11

| FO C AL S EG MENTAL G LOMERULOSCLEROS IS
The treatment of idiopathic steroid-resistant FSGS remains a worrying challenge for nephrologists. The potential usefulness of rituximab has also been explored in patients with steroid-dependent or steroid-resistant forms of nephrotic syndrome. 28 In a multicenter retro- 
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In a single-center cohort study by McAdoo et al of 66 patients with renal anti-neutrophil cytoplasm antibody-associated, a combined regimen of rituximab and cyclophosphamide proved to be potentially superior to current standards of care. Sixty-six patients were treated with a combination of oral corticosteroids, rituximab and lowdose pulsed intravenous cyclophosphamide, followed by a maintenance regimen of azathioprine and tapered steroid for the treatment of biopsy-proven renal involvement in AAV. Ninety-four per cent of patients achieved disease remission by 6 months. Patient and renal survival were 84% and 95%, respectively, at 5 years. Eighty-four per cent achieved ANCA-negative status and 57% remained B-cell deplete at 2 years, with low rates of major relapse. The serious infection rate during long-term follow-up was 1.24 per 10 patient-years.
Treatment with this regimen was associated with a reduced risk of death, progression to end-stage renal disease, and relapse, compared with propensity-matched patients enrolled in EUVAS trials. (375 mg/m 2 ), followed by full dose tacrolimus, mycophenolate mofetil, and prednisolone, followed by antigen-specific immunoadsorption, was used in four patients. The ABO-antibodies were readily removed by the antigen-specific immunoadsorption and were kept at a low level post transplantation by further adsorptions. There were no side effects, and all patients have normal renal-transplant function. There were no significant differences in the incidence of infection, vascular complications, biliary complications, and acute cellular rejection between the ABOi and non-ABOi group. The cumulative graft survival rates at 1, 3, and 5 years for the non-ABOi group were 92.1%, 87.0%, and 86.1%, and those for ABOi group were 82.8%, 82.8%, and 78.2%, respectively. They concluded that ABOi LDLT is a feasible option for pediatric end-stage liver disease patients. 43 The allograft survival and patient survival rates for published reports of ABOi renal transplantation using rituximab are summarized in Table 2 .
In HLA antibody incompatible renal transplants, rituximab is often given at the time of transplantation or even post transplant. 44 Use of rituximab as a treatment for acute renal allograft rejection has been purely descriptive, mainly single-case reports or case series. 47 In a randomized controlled trial, Zarkhin et al The term PTLD encompasses a heterogeneous group of lymphoproliferative disorders that may occur after transplantation of solid organs and hematopoietic cells. 51 PTLD has been reported in 1% of TA B L E 2 Results from adult ABOi renal transplant programs using rituximab 52 Rituximab has been demonstrated to be an effective treatment for PTLD. 53 In a retrospective study of eight patients with PTLD, Nieto-Rios et al concluded that the disorder can be managed successfully, with reduction of immunosuppression, conversion to m-TOR, and rituximab-based schemes. The first-line therapy consisted of rituximab given as a 375 mg/m 2 intravenous infusion for 4 hours, weekly. The overall response rate was 87.5% (62.5% complete response, 25% partial response). Survival was 87.5%, with a median follow-up of 34 months. 54 
| CON CLUS ION
Emerging evidence suggests that rituximab may be an effective and safe treatment in renal disorders and renal transplant. However, ideal dosing strategies and combination with other agents is still debatable.
Studies designed to answer these questions should delineate the best use of rituximab in nephrology, and randomized controlled trials are clearly required before accepting rituximab as a standard treatment.
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